|
Prostatic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Impact of total PSA and percent free PSA in the differentiation of prostate disease: a retrospective comparative study implicating neoplastic and non-neoplastic entities.
|
31786882 |
2020 |
|
Prostatic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The serum prostate specific antigen is the most widespread biomarker for prostate disease.
|
31833333 |
2019 |
|
Prostatic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Urologists must appreciate the effects of drugs provided for other diseases on PSA titers and be aware that sudden changes may not reflect underlying prostatic disease.
|
30370673 |
2019 |
|
Prostatic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The neutrophil/lymphocyte ratio did not discriminate between benign and malignant prostatic disease in patients with a PSA between 4-10ng/ml.
|
31759363 |
2019 |
|
Prostatic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Trichomonas vaginalis infection and prostate-specific antigen concentration: Insights into prostate involvement and prostate disease risk.
|
31376187 |
2019 |
|
Prostatic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Currently prostate-specific antigen is used for prostate cancer (PCa) screening, however it lacks the necessary specificity for differentiating PCa from other diseases of the prostate such as benign prostatic hyperplasia (BPH), presenting a clinical need to distinguish these cases at the molecular level.
|
29695737 |
2018 |
|
Prostatic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Men with a history of PC, radical prostatectomy or a "monitoring" PSA test for prostate disease were excluded.
|
29523809 |
2018 |
|
Prostatic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The outcome factor was ordering an "asymptomatic" PSA test (a PSA ordered for an indication that was not prostate-related symptoms or prostatic disease monitoring).
|
28869684 |
2017 |
|
Prostatic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Mean total PSA, free PSA, and free-total PSA ratio levels of quarry workers did not differ from those of controls and was below the cutoff for the risk of prostate diseases.
|
27362426 |
2017 |
|
Prostatic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Current prostate cancer (PCa) biomarkers such as PSA are not optimal in distinguishing cancer from benign prostate diseases and predicting disease outcome.
|
25686826 |
2015 |
|
Prostatic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Nonetheless, PSA shows weakness in discriminating between malign and benign prostatic disease or indolent and aggressive cancers.
|
24825472 |
2014 |
|
Prostatic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Prostate specific antigen (PSA) is the best-known member of the kallikrein-related peptidase family, with an established role as a prostatic disease biomarker.
|
21394741 |
2011 |
|
Prostatic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Prostate-specific antigen (PSA) is a serum marker that is widely used for the diagnosis of prostatic diseases.
|
22019475 |
2011 |
|
Prostatic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
PSA, as its name implies, is not specific for prostate cancer and as such is often found elevated in other prostatic diseases/symptoms associated with the aging male.
|
19507229 |
2009 |
|
Prostatic Diseases
|
0.100 |
GeneticVariation
|
group |
LHGDN |
Genetic variations in the PSA promoter are associated with serum PSA levels in men without prostatic disease.
|
12865450 |
2003 |
|
Prostatic Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Genetic variations in the PSA promoter are associated with serum PSA levels in men without prostatic disease.
|
12865450 |
2003 |
|
Prostatic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
To evaluate the diagnostic utility of free PSA (fPSA) and complexed PSA forms for identification of men with PCa in the low PSA range of <4 microg/l, total PSA (tPSA), alpha(1)-antichymotrypsin complexed PSA (PSA-ACT) and fPSA (Roche Elecsys [ES] system) as well as tPSA and complexed PSA (cPSA) (Bayer Immuno 1 system) were measured in archival serum samples from 31 untreated patients with PCa, 66 patients with BPH, and 90 men without prostatic disease.
|
11477592 |
2001 |
|
Prostatic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
To further elucidate the factors affecting the serum levels of this important tumor marker, we measured PSA concentrations in serum and in aspiration biopsies (tissue PSA; T-PSA) from patients with prostatic disease and correlated the values to tumor stage, cytological grade, and DNA ploidy.
|
10068342 |
1999 |
|
Prostatic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
However, serum PSA concentrations can be successfully used together with other methods in diagnosing prostatic diseases and in monitoring the successfulness of treatments for prostatic cancer.
|
7521173 |
1994 |